Upturn of obesity treatments even in 1st quarter considered as off-season

The obesity treatment market which has been depressed for a while has recently taken an upturn from the introduction of new drugs.

Since ‘Belviq(Ildong Pharmaceutical),’ the new obesity therapy which acquired approval from the U.S. FDA in 13 years of its launch, was launched in Korea on February last year, its market size has seemed getting bigger.

Even in the 1^st quarter which is known as an...